Lijnen P J, Amery A K, Fagard R H, Reybrouck T M, Moerman E J, De Schaepdryver A F
J Cardiovasc Pharmacol. 1979 Nov-Dec;1(6):625-32. doi: 10.1097/00005344-197911000-00003.
We studied the effects of labetalol, an alpha- and beta-adrenoceptor antagonist, on maximum exercise heart rate and on plasma renin, aldosterone, noradrenaline, and adrenaline levels at rest and during exercise in hypertensive patients. The dose of labetalol was doubled weekly from 0.3 to 2.4 g per day. The maximum exercise heart rate fell significantly during labetalol treatment, and there was a significant correlation between exercise tachycardia and the dosage of labetalol. Plasma renin activity and aldosterone concentration at rest decreased during treatment with labetalol. The exercise-induced increase in plasma renin activity was reduced by labetalol. Labetalol did not cause any significant changes in plasma noradrenaline and adrenaline at rest or during exercise.
我们研究了α、β肾上腺素能受体拮抗剂拉贝洛尔对高血压患者静息及运动时最大运动心率以及血浆肾素、醛固酮、去甲肾上腺素和肾上腺素水平的影响。拉贝洛尔的剂量每周翻倍,从每天0.3克增至2.4克。在拉贝洛尔治疗期间,最大运动心率显著下降,运动性心动过速与拉贝洛尔剂量之间存在显著相关性。拉贝洛尔治疗期间,静息时血浆肾素活性和醛固酮浓度降低。拉贝洛尔可减轻运动诱导的血浆肾素活性升高。拉贝洛尔对静息或运动时的血浆去甲肾上腺素和肾上腺素水平未产生任何显著变化。